

# Curriculum Vitae

**Angelo Dei Tos**, nato a Vittorio Veneto il 25 Agosto 1961, ivi residente in via Fogazzaro, 39.

## Recapito

UOC di Anatomia Patologica

ULSS 9 Treviso

Te. 0422 322707

Fax: 0422 322705

Email: [angelo.deitos@unipd.it](mailto:angelo.deitos@unipd.it)  
[angelopaolo.deitos@aulss2.veneto.it](mailto:angelopaolo.deitos@aulss2.veneto.it)

Mobile: + 39 348 5193527

## INCARICO ATTUALE

- Professore Ordinario di Anatomia Patologica, Università degli Studi di Padova, Direttore UOC di Anatomia Patologica dell'Ospedale Civile di Treviso dal 01.06..2016.

## CURRICULUM FORMATIVO

- Diploma di Liceo scientifico presso Liceo Scientifico Statale "Marcantonio Flaminio" - 1980.
- Laurea in Medicina e Chirurgia con punti 110/110 e lode - Università di Padova - 1986
- Specializzazione in Anatomia Patologica - Università di Padova -1989
- Specializzazione in Dermatologia – Università di Trieste - 2005
- Partecipazione ad Iniziative di Aggiornamento e Qualificazione e Stage teorico pratici presso istituzioni prevalentemente estere, tra le quali il St. Thomas's University Hospital di Londra, il Brigham and Women's Hospital, Harvard Medical School di Boston, e la Mayo Clinic di Rochester.
- Formazione come valutatore e responsabile di Sistemi Qualità in Sanità.
- Idoneità Nazionale Professore Ordinario di Anatomia Patologica

## CURRICULUM PROFESSIONALE E LAVORATIVO

- Ufficiale Medico del Corpo di Sanità dell'Esercito dal 22/07/1987 al 04/08/1998
- Assistente di ruolo del Servizio di Anatomia Patologica dell'Ospedale Civile di Conegliano dal 05/08/88 al 28/02/92.
- Aiuto di ruolo del Servizio di Anatomia Patologica dell'Ospedale Civile di Feltre dal 01/03/1992 al 30/04/93.
- Aiuto di ruolo del Servizio di Anatomia Patologica dell'Ospedale Civile di Conegliano dal 01/05/93 al 19/10/94.
- Dirigente Medico di I° Livello, del Servizio di Anatomia Patologica dell'Ospedale Civile di Treviso dal 20/10/94 al 11/12/2002.
- Direttore UOC di Anatomia Patologica dell'Ospedale Civile di Treviso dal 12/12/02 al 31.05.2016

- Direttore Dipartimento di Patologia Clinica Azienda ULSS 9 dal 2008 al 31/12/2009
- Direttore Dipartimento Funzionale di Oncologia Azienda ULSS 9 (dal 01/01/2010 al 31.12.2016)
- Direttore Scientifico del Registro Tumori della Regione Veneto (2013-2015).
- Coordinatore diagnostica patologica Rete Nazionale Tumori Rari

## **CURRICULUM SCIENTIFICO E DI RICERCA**

- Autore di **292 pubblicazioni scientifiche** “peer reviewed” in maggioranza edite in riviste specialistiche di rilevanza internazionale.
- Svolge dal 1996 **attività di consulenza diagnostica** su casi di patologia oncologica mesenchimale e su tumori rari provenienti da istituzioni italiane ed estere e coordina la diagnostica patologica della Rete Nazionale Tumori Rari.
- Membro della “faculty” WHO per la classificazione dei tumori mesenchimali (dal 2000).

## **ATTIVITA' DIDATTICA**

- Professore Ordinario di Anatomia Patologica, Università degli Studi di Padova. Dall'anno accademico AA 2016/17
- Professore a contratto di Anatomia Patologica, Facoltà di Medicina, Università di Padova, Sezione di Treviso. AA. 2014-2016
- Professore a Contratto di Tecnica e Diagnostica Immunoistochimica, Scuola di Specializzazione in Anatomia Patologica, Università di Padova. 2001-2010
- Professore a contratto di Genetica. Scuola di specializzazione in Anatomia Patologica. Università di Sassari. 1997-2006.
- Professore a contratto di fisiopatologia generale. Corso di Laurea in Fisioterapia. Università di Padova. 1998-2010.
- Professore a contratto di Microbiologia medica. Diploma di Fisioterapia. Università di Padova. 1997-1998.
- Titolare del corso breve “Small Round Cell Neoplasms of Soft Tissues: A Diagnostic Approach” presso la Divisione Americana e Canadese dell'International Academy of Pathology (2001-2005).
- Docente di Patologia Generale ed Igiene, Scuola per terapisti della Riabilitazione, La Nostra Famiglia, Conegliano. 1989-1997

**RELATORE/DOCENTE** invitato a riferire su temi di competenza in Congressi Nazionali ed Internazionali nonché presso Istituzioni Universitarie Nazionali ed Estere

## **ORGANIZZATORE DEI SEGUENTI EVENTI FORMATIVI:**

- “**Diagnostic Histopathology of Soft Tissue Tumours**”. Conegliano.12-13 Giugno 1992. In collaborazione con St-Thomas & Guy's Hospital Londra..
- “**Diagnostic Histopathology of Soft Tissue Tumors**”. Treviso, 13-14 aprile 1996. In collaborazione con Harvard Medical School, Boston USA.

- **“Diagnostic Histopathology of Tumors and Tumor-like Condition of Bone”**. Treviso, 2-3 ottobre 1997. In collaborazione con Mayo Clinic Medical Laboratories.
- **“Diagnostic Histopathology of Tumors of the Nervous System”**. Treviso, 21-22 maggio 1998. In collaborazione con Mayo Clinic Medical Laboratories.
- **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 20-21 maggio 1999. In collaborazione con Harvard Medical School, Boston USA.
- **“Diagnostic Histopathology of Inflammatory Skin Diseases”**. Treviso, 22-23 maggio 2000. In collaborazione con Harvard Medical School, Boston USA.
- **“Diagnostic Histopathology of Tumors and Tumor-like Condition of Bone”**. Treviso, 18-19 maggio 2001. In collaborazione con Mayo Clinic Medical Laboratories. (11 crediti formativi ECM)
- **“Diagnostic Immunohistochemistry”**. Treviso, 11-12 ottobre 2001. (11 crediti formativi ECM).
- **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 18-19 aprile 2002. In collaborazione con Harvard Medical School, Boston USA. (14 crediti formativi ECM).
- **“Riunione autunnale IAP/SIAPEC”**. Treviso, 27-29 ottobre 2002. (12 crediti formativi ECM).
- **“Diagnostic Histopathology of Malignant Lymphomas”**. Treviso 10-11 aprile 2003. In collaborazione con il Queen Elizabeth Hospital, Kowloon, Hong Kong.
- **“Diagnostic Histopathology of Non-neoplastic and neoplastic Lung Diseases”**. Treviso, 28-29 ottobre 2004. In collaborazione con Mayo Clinic Medical Laboratories. (11 crediti formativi ECM)
- **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 5-6 maggio 2005. In collaborazione con Harvard Medical School, Boston USA (12 crediti formativi ECM).
- **“Diagnostic Immunohistochemistry”**. Treviso, 26-27 ottobre 2005. (11 crediti formativi ECM)
- **International Course on Surgical Pathology**. Joint event cosponsored by Mayo Clinic. Treviso, 2-5 maggio 2006.
- **ESMO International Symposium on GIST and Sarcomas**. Milano, 15-18 giugno 2006
- **Update on Surgical Pathology**. Treviso 8-9 novembre 2006. In collaborazione con il Queen Elizabeth Hospital, Kowloon, Hong Kong. (7 crediti formativi ECM)
- **Corso residenziale su patologia mesenchimale “I.D.E.A”**. Treviso, 29 novembre-2 dicembre 2006 (36 crediti formativi ECM).
- **“Diagnostic Histopathology of Tumors of the Uterus and Ovary”**. Treviso, 26-27 aprile 2007. In collaborazione con Harvard Medical School, Boston USA (10 crediti formativi ECM).
- **Corso residenziale su patologia mesenchimale “I.D.E.A”**. Treviso, 14 -17 maggio 2007 (36 crediti formativi ECM).
- **Corso residenziale su patologia mesenchimale “I.D.E.A”**. Treviso, 14 -17 maggio 2008 (36 crediti formativi ECM).
- **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 8-9 maggio

2008. In collaborazione con Harvard Medical School, Boston USA (12 crediti formativi ECM).
- **ESMO International Symposium on GIST and Sarcomas**. Milano, 13-14 maggio 2008
  - **“Diagnostic Histopathology of neoplastic and nonneoplastic conditions of GI Tract”**. Treviso, Settembre 2008. In collaborazione con Cleveland Clinic, Cleveland USA (10 crediti formativi ECM).
  - **Corso residenziale su patologia mesenchimale “I.D.E.A”**. Treviso, April 2009 (36 crediti formativi ECM).
  - **ESMO International Symposium on GIST and Sarcomas**. Milano, Marzo 2010
  - **Corso residenziale su patologia mesenchimale “I.D.E.A”**. Treviso, Maggio 2010 (36 crediti formativi ECM).
  - **“Diagnostic Surgical Pathology”**. Treviso, 9-11 dicembre 2010. In collaborazione con la Cleveland Clinic, Cleveland USA (12 crediti formativi ECM).
  - **Corso residenziale su patologia mesenchimale “I.D.E.A”**. Treviso, Aprile 2011 (36 crediti formativi ECM).
  - **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 8-9 maggio 2011. In collaborazione con Harvard Medical School, Boston USA (9 crediti formativi ECM).
  - **ESMO International Symposium on GIST and Sarcomas**. Milano, 7-10 Marzo 2012
  - **“Diagnostic Histopathology of GYN Tumors”**. Treviso, 29-30 Maggio 2012. In collaboration with Harvard Medical School, Boston USA (9 crediti formativi ECM).
  - **“Diagnostic Histopathology of Breast Tumors”**. Treviso, 29-30 Novembre 2012. In collaboration with Harvard Medical School, Boston USA (9 crediti formativi ECM).
  - **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 8-9 maggio 2013. In collaborazione con Harvard Medical School, Boston USA (9 crediti formativi ECM).
  - **ESMO International Symposium on GIST and Sarcomas**. Milan, 18-19 March 2014
  - **“Diagnostic Histopathology of Gynecologic tumors”**. Treviso, 27-28 novembre 2014. In collaborazione con Harvard Medical School, Boston USA (9 crediti formativi ECM).
  - **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 7-8 maggio 2015. In collaborazione con Harvard Medical School, Boston USA 12 crediti formativi ECM).
  - **“AACR Meeting, Basic Science of Sarcomas”**. Salt Lake City, USA, 3<sup>rd</sup>-4<sup>th</sup> November, 2015
  - **“20<sup>th</sup> Connective Tissue Oncologic Society Annual Meeting”**, Salt Lake City, USA, 5<sup>th</sup>-7<sup>th</sup> November, 2015.
  - **“Diagnostic Histopathology of Tumors of Central Nervous System”**. Treviso, October 2016. In collaboration with Mayo Clinic (12 crediti formativi

ECM).

- **“Diagnostic Histopathology of Soft Tissue Tumors”**. Treviso, 12-13 ottobre 2017. In collaborazione con Harvard Medical School, Boston USA 12 crediti formativi ECM).

#### **PREMI E RICONOSCIMENTI:**

- Premio Europeo “Giovani Medici” CRS AMPLIFON - 1988
- Premio Lega Italiana per la Lotta Contro i Tumori -1992
- Roger Cotton Histopathology prize - 2010

#### **AFFILIATO ALLE SEGUENTI SOCIETA' SCIENTIFICHE:**

- **United States and Canadian Academy of Pathology** (Membro del corpo docente quinquennio 2001-2005 e 2012-2014) dal 1994.
- **International Society of Bone and Soft Tissue Pathology** (Past President).
- **European Society of Pathology** (Chairman del Gruppo operativo di studio delle neoplasie mesenchimali) dal 1999
- **Connective Tissue Oncologic Society**: Past President
- **Società Italiana di Anatomia Patologica e Citodiagnostica** (membro del Consiglio direttivo nazionale – trienni 2002-2004 e 2005-2007).
- **Arthur Purdy Stout Society of Surgical Pathology** (Council Member) dal 2000
- **International Skeletal Society** dal 1999
- **European Society of Medical Oncology**: faculty member 2006-2015. Media Ambassador (2010)

#### **EDITORIAL BOARD**

- **Editor in Chief: “Clinical Sarcoma Research”**
- **“American Journal of Clinical Pathology”**
- **“Journal of Pathology”**
- **“Advances in Anatomic Pathology”**
- **“Journal of Clinical pathology”**
- **“Applied immunohistochemistry and molecular morphology”**
- **“Pathologica”**
- **“Seminars in Diagnostic Pathology”**
- **“Virchow Archiv”**
- **“Surgical Oncology” – Section Editor**

#### **PROGETTI DI RICERCA**

- Chairman “Dissemination and spread of excellence program” del progetto quadro CEE KP6: Eurobonet (Finanziamento quinquennale di un network europeo di eccellenza nella diagnosi e ricerca della patologia tumori ossea (finanziamento: € 12.600.000,00).
- Chairman dello studio retrospettivo nazionale sui Tumori Gastrointestinali

“Register”

- Chairman WP4 progetto europeo “Rarecare”
- Titolare dell’analisi centralizzata dell’espressione di EGFR nel carcinoma avanzato del colon trattato con anticorpi monoclonali umanizzati contro EGFR (cetuximab).
- Chairman “Dissemination and spread of excellence program” del progetto quadro CEE KP7: EUROSARC
- Chairman Transverse Task Force “Pathology” **European Reference Network “EURACAN”**.

## Pubblicazioni

1. "Descrizione di un caso di mesotelioma pleurico insorto in un soggetto a basso rischio specifico". Bernardi M, Della Libera D, Dei Tos AP.  
**Acta Oncol 1988; 9:59-62.**
2. "Lo sviluppo embriologico e fetale della laringe". Carlon G, Bertondini A, Della Libera D, Dei Tos AP.  
**In Carlon G, Serafini I. Il Carcinoma Sopraglottico. Padova Piccin, 1989:71-81.**
3. "A whole organ sectioning method for histologic examination of laryngeal and hypopharyngeal specimens". Carlon G, Della Libera D, Dei Tos AP.  
**In Sacristan T (ed) Otorhino- laryngology, Head and Neck Surgery. 1990;2367-2371**
4. "Advanced glottic carcinoma: treatment, pathology and follow-up". Serafini I, Ghirardo R, Pazzia T, Bittesini L, Della Libera D, Dei Tos AP.  
**In Sacristan T (ed) Otorhinolaryngology, Head and Neck Surgery, 1990:2461-3.**
5. "Il carcinoma squamoso verrucoso della glottide". Dei Tos AP.  
**In Serafini I (ed) Il carcinoma glottico. Piccin Padova 1991.**
6. "Anatomia della regione glottica". Bittesini L, Dei Tos AP.  
**In Serafini I (ed) Il carcinoma glottico. Piccin Padova, 1991.**
7. "Il carcinoma glottico ad estensione sopraglottica". Della Libera D, Dei Tos AP.  
**In Serafini I (ed) Il carcinoma glottico. Piccin Padova, 1991.**
8. "Proposta per un pT clinicamente orientato". Bittesini L. Dei Tos AP.  
**In Serafini I (ed) Il carcinoma glottico. Piccin Padova, 1991.**
9. "Sul trattamento del carcinoma adenoido-cistico laringeo". Serafini I, Lucioni M, Bittesini L, Dei Tos AP.  
**Acta Otorhinol Ital 1991, 11:13-24.**
10. "Malignant melanoma showing rhabdoid differentiation. Further evidence of a non- specific histologic pattern". Bittesini L, Dei Tos AP, Fletcher CDM.  
**Histopathology 1992;20:167-170.**
11. "Aspiration Biopsy cytology of malignant papillary neoplasms of the breast". Dei Tos AP, et al.  
**Diagn Cytopathol, 1992;8:580-584.**
12. "p53 expression in non neoplastic lesions and benign and malignant neoplasms of soft tissue". Dei Tos AP, et al.  
**Histopathology, 1993;22:45- 50.**

13. "Chondrosarcoma of the larynx: a case report with clinicopathologic correlation". Ghirardo R, Lucioni M, Dei Tos AP, Bittesini L  
**In G. Motta (ed). The new frontiers of ORL in Europe. Monduzzi, 1992, 411- 414.**
14. "Cytodiagnosis of primitive carcinoid tumor of the wirsung duct". Dei Tos AP, et al.  
**Diagn Cytopathol 1993;9:471-474.**
15. "KP1 expression in benign neural tumours". Dei Tos AP, et al.  
**Histopathology 1993;23:185- 187.**
16. "Pancreatic (acinar) metaplasia of the gastric mucosa. An immunocytochemical and ultrastructural study". Doglioni C, Laurino L, Dei Tos AP, et al  
**Am J Surg Pathol 1993;17:1134-1143.**
17. "Fibroepithelial tumour of the breast with digital fibroma-like stromal component. A morphological, immunocytochemical and ultrastructural analysis". Dei Tos AP, et al.  
**Am J Surg Pathol 1994;18:296-301.**
18. "Aspiration biopsy cytology of malignant papillary breast neoplasms". Dei Tos AP.  
**Am Soc Clin Pathol Check Sample Series 1994, C-94-10.**
19. "The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinico-pathologic correlates, with particular reference oestrogen receptor status". Doglioni C, Dei Tos AP, et al.  
**Virchows Arch (A) 1994;424:47-51.**
20. "UV- induced p53 mutations in atypical fibroxanthoma". Dei Tos AP, et al.  
**Am J Pathol 1994;145:11-17.**
21. "Aspiration biopsy cytology of tubular carcinoma of the breast". Dei Tos AP, et al.  
**Diagn Cytopathol 1994; 11:146-150.**
22. "Spindle cell liposarcoma: a hitherto unrecognized variant of well-differentiated liposarcoma: analysis of six cases". Dei Tos AP, et al.  
**Am J Surg Pathol 1994; 18:913-921.**
23. "Perineurioma (storiform perineural fibroma): clinicopathological analysis of four cases". Mentzel T, Dei Tos AP, Fletcher CDM.  
**Histopathology 1994; 25:261-267.**
24. "Aspiration biopsy cytology of intranodal myofibroblastoma". Dei Tos AP, et al.



**Diagn Cytopathol 1995; 13:134-138.**

25. "Fibroepithelial tumor". Author's reply. Dei Tos AP, et al.  
**Am J Surg Pathol 1995; 19:730-732.**
26. "Giant cell angiofibroma. A distinctive orbital tumor in adults". Dei Tos AP, et al.  
**Am J Surg Pathol 1995; 1286-1293.**
27. "Immunohistochemical demonstration of glycoprotein p30/32<sup>MIC2</sup> (CD99) in synovial sarcoma. A potential cause of diagnostic confusion". Dei Tos AP, et al.  
**Appl Immunohistochem 1995; 3:168-173.**
28. "Tumor suppressor genes and related molecules in leiomyosarcoma". Dei Tos AP, et al.  
**Am J Pathol 1996; 148:1037-1045.**
29. "S-100 protein staining in liposarcoma. Its diagnostic utility in the high grade myxoid (round cell) variant". Dei Tos AP, et al.  
**Appl Immunohistochem 1996; 4:95-101.**
30. "S-100 protein reactivity in synovial sarcomas. A potentially frequent diagnostic pitfall. Immunohistochemical analysis of 100 cases". Dei Tos AP et al.  
**Appl Immunohistochem 1996; 4:167-175.**
31. "Calretinin: a novel immunocytochemical marker for mesothelioma". Doglioni C, Dei Tos AP, et al.  
**Am J Surg Pathol 1996; 20:1037-1046.**
32. "Uterine smooth muscle neoplasms: a diagnostic dilemma". Dei Tos AP.  
**Pathologica 1996; 88:141-143.**
33. "Liposarcoma: controversies and conceptual problems". Editorial. Dei Tos AP.  
**Pathologica 1996; 88: 467-471.**
34. "Malignant fibrous histiocyoma: a vanishing entity"? Dei Tos AP.  
**Pathologica 1996; 88:522-524.**
35. "Desmoplastic small round cell tumors of the paratesticular region. A report of six cases". Cummings OW, Ulbright TM, Young RH, Dei Tos AP, Fletcher CDM, Hull MR.  
**Am J Surg Pathol 1997; 21:219-225.**
36. "Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma". Dei Tos AP, et al.  
**J Pathol 1997; 181:8-13.**
37. G. "bcl-2 expression in pleural and extrapleural solitary fibrous tumor". Chilosi M, Facchetti F, Dei Tos AP, et al.  
**J Pathol 1997, 181: 171-181.**

38. "Kaposiform hemangioendothelioma in adults: clinicopathological and immunohistochemical analysis of three cases". Mentzel T, Mazzoleni G, Dei Tos AP, Fletcher CDM.  
**Am J Clin Pathol 1997; 108:450-455.**
39. "Extraskelatal myxoid chondrosarcoma: an immunohistochemical reappraisal of 39 cases". Dei Tos AP et al.  
**Appl Immunohistochem 1997; 5:73-77.**
40. "The role of cytogenetics in the classification of soft tissue tumours". Dei Tos AP, et al.  
**Virchows Arch 1997; 431:83-94.**
41. "Molecular aberrations of the G1-S cell cycle checkpoint in myxoid and round cell liposarcoma". Dei Tos AP, et al.  
**Am J Pathol 1997; 151:1531-1539.**
42. "Immature teratoma of the pineal gland with i(12p)". Dal Cin P, Dei Tos AP, et al.  
**Acta Neuropathol 1998; 95:107-110.**
43. "Fibrosarcomatous ("high grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance". Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CDM.  
**Am J Surg Pathol 1998; 22:576-587.**
44. "Calretinin: a novel tool for diagnostic immunohistochemistry". Dei Tos AP, et al.  
**Adv Anat Pathol 1998; 5:61-66.**
45. "bcl.2 expression in synovial sarcoma. Author's reply". Chilosi M, Dei Tos AP, et al.  
**J pathol 184; 337-340.**
46. "Cyclin D3 expression in human normal tissue and neoplasms". Doglioni C, Chiarelli C, Macri E, Dei Tos AP, et al.  
**J Pathol 1998; 185; 159-166.**
47. "Primary liposarcoma of the skin: a rare neoplasms with unusual high grade features". Dei Tos AP, et al.  
**Am J Dermatopathol 1998; 20:332-338.**
48. "Synovial sarcoma of the larynx and hypopharynx: pathologic and diagnostic evaluation". Dei Tos AP, et al.  
**Ann Otol Rhinol Laryngol 1998; 107:1080-1085.**
49. "News and confirmations in mesenchymal neoplasia". Dei Tos AP.  
**Pathologica 1998; 90: 54-56.**

50. "Amplification and expression of the HMGIC gene in a benign endometrial polyp". Dal Cin P, Wanschura S, Kazmierczak B, Tallini G, Dei Tos AP, et al.  
**Genes Chromosomes Cancer 1998; 22:95-99.**
51. "Malt Lymphoma: an update". Doglioni C, Dei Tos AP, Barbareschi M.  
**Pathologica 1998; 90:313-317.**
52. "Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis". Foschini MP, Macchia S, Losi L, Dei Tos AP, et al.  
**Virchows Arch 1998; 433: 267-273.**
53. "The relevance of genetics and molecular pathology in mesenchymal tumours". Dei Tos AP, et al.  
**Adv Clin Pathol 1998; 2:197-204.**
54. "La diagnosi neuropatologica e le sue implicazioni terapeutiche". Giannini C, Dei Tos AP.  
**Pathologica 1998 90; 408-411.**
55. "Citogenetica di tumori del sistema nervoso centrale: studio casistico e revisione della letteratura". Losi L, Buonamici L, Dal Cin P, Giannini C, Dei Tos AP, et al.  
**Pathologica 1999; 91:249-255.**
56. "Twist is a potential oncogene that inhibits apoptosis". Maestro R, Dei Tos AP, et al.  
**Genes Dev 1999; 13:2207-2217.**
57. "Isolated brain metastasis of malignant choroidal melanoma 27 years after enucleation". Midenà E; de Belvis V; Dei Tos AP et al.  
**Arch Ophthalmol, 1999; 117:11, 1553-1556.**
58. "Repeat percutaneous tracheostomy with the Ciaglia technique after translaryngeal tracheostomy". Mazzon D; Zanardo G; Dei Tos AP.  
**Intensive Care Med, 1999; 25: 639.**
59. Adipocytic tumors: new entities and evolving concepts. Dei Tos AP.  
**Rev Esp Patol 1999, 32:271-282.**
60. "Absence of S-100 protein immunoreactivity in cellular blue nevus: a potential diagnostic pitfall". Dei Tos AP, et al.  
**Applied Immunohistochem 1999; 7: 255-259.**
61. "Primary giant cell tumor of soft tissue. A clinicopathologic analysis of 21

cases". Oliveira A, Dei Tos AP, et al.  
**Am J Surg Pathol. 2000; 24:248-256.**

62. "Coordinated expression and amplification of the MDM2, CDK4 and HMGI-C genes in atypical lipomatous tumors". Dei Tos AP et al.  
**J Pathol 2000, 180; 531-536.**

63. "Liposarcoma: new entities and evolving concept. Dei Tos AP.  
**Ann Pathol 2000; 4:252-266.**

64. "Primary giant cell tumors of soft tissue". Author's reply. Oliveira A, Dei Tos AP, Fletcher CDM, Nascimento A.  
**Am J Surg Pathol 2000; 24:1175-1176.**

65. "Lipomatous tumours". Dei Tos AP.  
**Curr Diagn Pathol 2001; 7:8-16. 1997-1998.**

66. "p53 expression in pleomorphic xanthoastrocytoma". Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD.  
**Neurogenetics 2001; 3: 159-162.**

67. "Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature". Zembowicz A, McCusker M, Chiarelli C, Dei Tos AP, et al.  
**Am J Dermatopathol 2001; 23:167-75**

68. "Determinazione di HER2 nel carcinoma mammario: quale approccio metodologico? " Orvieto E, Dei Tos AP.  
**Pathologica 2001; 93:183-188.**

69. "Well differentiated liposarcoma (atypical lipomatous tumors)". Laurino L, Furlanetto A, Orvieto E, Dei Tos AP.  
**Sem Diagn Pathol 2001; 18:258-262.**

70. "Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia". Orvieto E, Furlanetto A, Laurino L, Dei Tos AP.  
**Sem Diagn Pathol 2001; 18: 267-273.**

71. "Primary peripheral PNET/Ewing's sarcoma of the dura: a clinicopathologic entity distinct from central PNET". Dedeurwaerdere F, Giannini C, Sciò R, Rubin BP, Perilongo G, Borghi L, Ballotta ML, Cornips E, Demunter A, Maes M, Dei Tos AP.  
**Mod Pathol 2002, 15: 673-678.**

72. "Squamous cell carcinoma arising in a ciliated hepatic foregut cyst". A. Furlanetto, Dei Tos AP.  
**Virchows Arch 2002, 441:296-8.**

73. Atypical lipomatous tumor and dedifferentiated liposarcoma: are they still

controversial concepts? Dei Tos AP.  
**Histopathology 2002, 41 (suppl): 227-230.**

74. "The reappraisal of GIST: from Stout to the KIT revolution". Dei Tos AP.  
**Virchows Arch 2003; 443-421-428.**
75. Role of HER-2 in the treatment of breast carcinoma Dei Tos AP.  
**Pathologica. 2003; 95:278.**
76. GIST: from diagnosis to molecular therapy. Dei Tos AP.  
**Pathologica. 2003;95:251.**
77. The utility of the immunohistochemical detection of Fli-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Rossi S., Orvieto E., Furlanetto A., Laurino L., Ninfo V, Dei Tos AP.  
**Mod Pathol 2004; 17: 547-552.**
78. Changing concepts in the pathological basis of Soft Tissue and Bone sarcoma treatment. Hogendoorn PCW, Collin F, Daugaard S, Dei Tos AP, Fisher C, Schneider U, Sciot R.  
**Eur J Cancer 2004, 40:1644-54.**
79. Biological fate of tissue-engineered porcine valvular conduits xenotransplanted in the sheep thoracic aorta. Conconi MT, Rocco F, Spinazzi R, Tommasini M, Valfrè C, Busetto R, Polesel E, Albertin G, Dei Tos A, Iacopetti I, Cecchetto A, Zussa C, Grigioni M, Parnigotto PP, Nussdorfer GG.  
**Int J Mol Med. 2004, 14:1043-1048.**
80. "Ancillary" methods, marketing, and health care models. To be precise: between ethics and marketing, an investigation of quality or of profit? Chilosi M, Dei Tos AP, Doglioni C.  
**Pathologica 2004; 96:43-44.**
81. "Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin". Lazar AJ, Calonje E, Grayson W, Dei Tos AP, Mihm MC Jr, Redston M, McKee PH.  
**J Cutan Pathol. 2005; 32:148-157.**
82. "Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of the 20-21 March 2004, under the auspices of ESMO." Blay J-Y, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP; Emile J-F, Gronchi A, Hogendoorn AP, Joensuu H, Le Cesne A, Mac Clure J, Maurel J, Nupponen I, Ray-Coquard I, Reichart P, Sciot R, Stroobants S, van Glabbeke A, van Oosterom A, Demetri GD.  
**Ann Oncol 2005; 16:566-578.**
83. "Biologia molecolare dei GIST. In M Lopez (ed) GIST: tumori stromali

gastrointestinali.” Dei Tos AP, Ninfo V. S.  
**Editrice Universo Roma, 2005, pp. 9-14**

84. New diagnostic markers: podoplanin-d2-40. Chilosi M, Doglioni C, Dei Tos AP.  
**Pathologica. 2005; 97(3):158-9**
85. “Assessing Epidermal Growth Factor Receptor expression in tumours: what is the value of current test methods?” Dei Tos AP, Ellis I.  
**Eur J Cancer 2005; 41:1383-1392.**
86. Characterization of thyroid “follicular neoplasms” in fine needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M.  
**Endocr Relat Cancer 2005 12:305-317.**
87. Rabbit Monoclonal Antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonals. Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP.  
**Am J Clin Pathol 2005; 124:295-302.**
88. “Morphologic and Immunophenotypic Diversity in Ewing Family Tumors: A Study of 66 Genetically Confirmed Cases” Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, Weiss SW.  
**Am J Surg Pathol, 2005; 29:1025-1033.**
89. Aquaporin 1 expression in cystic hemangioblastomas. Longatti P, Basaldella L, Orvieto E, Dei Tos AP, Martinuzzi A.  
**Neurosci Lett. 2006 16;392:178-80.**
90. Myopericytoma of skin and soft tissues: clinicopathologic and immunohistochemical study of 55 cases. Mentzel T, Dei Tos AP, Sapi Z, Kutzner H  
**Am J Surg Pathol, 2006; 30:104-113..**
91. Classification of pleomorphic sarcomas: where are we now? Dei Tos AP.  
**Histopathology 2006; 48:51-62.**
92. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Cserni G, Dei Tos AP, Fortunati N, Catalano MG, Bussolati G.  
**Mod Pathol. 2006;19:599-606.**
93. Fatty acid synthase is overexpressed in gastrointestinal stromal tumors

(GIST). Rossi S, Ou W, Tang D, Bhattacharya D, Dei Tos AP, Fletcher JA, Loda M.

**J Pathol 2006, 209:369-375**

94. Jaw1/LRMP: a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. Tedoldi S, Paterson JC, Cordell J, Tan S-Y, Jones M, Manek S, Dei Tos AP, Masir N, Natkunam Y, Robertson H, Pileri SA, Facchetti F, Hansmann M.L, Mason DY, Marafioti T.

**J Pathol 2006, 209:454-463**

95. Aquaporin(s) expression in choroid plexus tumours. Longatti P, Basaldella L, Orvieto E, Dei Tos A, Martinuzzi A.

**Pediatr Neurosurg. 2006;42:228-33.**

96. Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: Evidence of simultaneous expansion of two independent clones. Gottardi M, Gattei V, Degan M, Bomben R, Zucchetto A, Tecchio C, Laurino L, Zanatta L, Dei Tos AP, Mordacchini M, Canal F, Gherlinzoni F.

**Leuk Lymphoma. 2006 May;47:885-889.**

97. Causes of arachnoid cyst development and expansion. Basaldella L, Orvieto E, Dei Tos AP, Dalla Barbera M, Valente ML, Longatti PL.

**Neurosurg Focus 2007; 22:1-7.**

98. Small round cell neoplasms of soft tissue: an integrated diagnostic approach. Rossi S, Nascimento AG, Canal F, Dei Tos AP.

**Curr Diagn Pathol 2007; 13:150-163.**

99. Cell membrane reactivity of Mib-1 antibody to Ki67 in human tumors: fact or artifact? Leonardo E, Volante M, Barbareschi M, Cavazza A, Dei Tos AP, Bussolati G, Papotti M.

**Appl Imm Mol Morph; 2007, 15:220-223.**

100. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Dei Tos AP.

**Int J Biol Markers, 2007: Jan-Mar;22 Suppl 4:S3-9.**

101. Patients With Advanced Stage Breast Carcinoma Immunoreactive to Biotinylated Herceptin Are Most Likely to Benefit From Trastuzumab-based Therapy: An Hypothesis-generating Study. Sapino A, Montemurro F, Marchiò C, Viale G, Kulka J, Donadio M, Bottini A, Botti G; Dei Tos AP, Bersiga A, Di Palma S, Truini M, Sanna G, Aglietta M, Bussolati G.

**Ann Oncol. 2007;18(12):1963-8.**

102. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis with other fibrosing disease. Corradi D, Maestri R, Palmisano A, Bosio S, Greco P, Manenti I, ferretti S, Cobelli R, Moroni G, Dei Tos AP, Buzio C, Vaglio A.  
**Kidney International, 2007;72:742-53.**
103. Causes of arachnoid cyst development and expansion. Basaldella L, Orvieto E, Dei Tos AP, Della Barbera M, Valente M, Longatti P.  
**Neurosurg Focus. 2007; 15;22:E4.**
104. Advances in gastrointestinal stromal tumor therapy. Rossi S, Dei Tos AP.  
**Adv Anat Pathol. 2007 ;14:302.**
105. Chromosomal imbalances and cytogenetic progression in gastrointestinal stromal tumor. Rossi S, Dei Tos AP.  
**Adv Anat Pathol. 2007;14:301-302.**
106. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Rossi S, Szuhai K, Ijszenga M, Tanke HJ, Zanatta L, Sciot R., Fletcher CDM, Dei Tos AP, Hogendoorn PCW.  
**Clin Cancer Res 2007, 2007 15;13(24):7322-8.**
107. Primary cardiac onset of disseminated Burkitt's lymphoma Stefani PM, Laurino L, Zanatta L, Valori L, Dei Tos AP, Gherlinzoni F.  
**Ann Hematol. 2008;87(6):487-488**
108. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group.  
**Ann Oncol. 2008 Suppl 2:89-93.**
109. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group.  
**Ann Oncol. 2008 Suppl 2:35-8.**
110. Multiple primary sporadic GIST in the adult: an underestimated entity. Gasparotto D, Rossi S, Bearzi I, Doglioni C, Marzotto A, Hornick JL, Grizzo A, Sartor C, Mandolesi A, Sciot R, Debiec-Rychter M, Dei Tos AP, Maestro R  
**Clin Cancer Res 2008: 15; 5715-21.**
111. Atypical cystic meningioma overexpressing AQP1 in early infancy: case report with literature review. Marton E, Feletti A, Basaldella L, Dei Tos AP, Bendini M, Longatti P.



**Acta Paediatr. 2008;97:1145-1149.**

112. Aleukemic granulocytic sarcoma with associated T-cell lymphoblastic lymphoma in the same lymph node: morphologic features and molecular signatures. Licci S, Canal F, Dei Tos AP, Fedrigo M, Gherlinzoni F, Brenna A, Zanatta L, Rossi S.  
**Leuk Lymphoma. 2008;49:1411-1415.**
113. Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Gottardi M, Danesin C, Canal F, Dei Tos AP, Maria Stefani P, Calistri E, Salvadori U, Gherlinzoni F.  
**Leuk Lymphoma. 2008; 25:1-3**
114. Desmoid-type fibromatosis: from morphology to molecular genetics: Rossi S, Laurino L, Dei Tos AP.  
**Diagnostic Histopathology 2008; 14:546-551.**
115. Retrospective evaluation of clinical outcomes in patients with HER2-positive breast cancer progressing on Trastuzumab-based therapy in the pre-Lapatinib era. Monetmurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, Dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Claravezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M.  
**Clinical Breast cancer 2008; 8:436-442.**
116. The VEGF-System in Primary Pulmonary Angiosarcomas and Haemangioendotheliomas: New Potential Therapeutic Targets? Stacher E, Gruber-Mösenbacher U, Halbwedl I, Dei Tos AP, Cavazza A, Papotti M, Carvalho L, Huber M, Leander Ermert L, Popper HH.  
**Lung Cancer. 2009, 65:49-55.**
117. Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP  
**Hum Pathol. 2009;40:1040-4**
118. Primary leptomenigeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. Rossi S, Rodriguez FJ, Mota RA, Dei Tos AP, Di Paola FD, Bendini M, Agostini S, Longatti P, Jenkins RB, Giannini C.  
**Acta Neuropathol. 2009 Jun 27. [Epub ahead of print]**
119. Epithelioid soft tissue tumors. Dei Tos AP, Wagner AJ, Modena P, Comandone A, Leyvraz S.

**Semin Oncol. 2009; 36:347-357.**

120. Small round cell sarcomas. Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall KS.  
**Semin Oncol. 2009;36:338-346.**
121. Diffuse leptomeningeal glioneuronal tumors: a new entity? Rossi S, Rodriguez F, Dei Tos AP, Di Paola F, Bendini M, Jenkins R, Giannini C.  
**Brain Pathol. 2009;19(4):745;**
122. Benign cartilaginous tumors of bone: from morphology to somatic and germ-line genetics. Romeo S, Hogendoorn PC, Dei Tos AP.  
**Adv Anat Pathol. 2009 ;16:307-15.**
123. Primary Cutaneous Leiomyosarcoma: Clinico-pathologic analysis of 36 cases Massi, D, Franchi A, Alos L, Cook M, Di Palma S, Enguita AB, Ferrara G, Kazakov DV, Mentzel T, Michal M, Panelos J, Rodriguez-Peralto J-L, Santucci M, Tragni G, Zioga A, Dei Tos AP.  
**Histopathology 2010;56:251-62.**
124. The marriage between pathology and genetics: are we ready for clinical use? Dei Tos AP.  
**Ann Surg Oncol. 2010;17:668-9.**
125. Soft tissue tumors associated with EWSR1 translocation. Romeo S, Dei Tos AP.  
**Virchows Arch. 2010;456:219-34.**
126. PML down-regulation in soft tissue sarcomas. Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G.  
**J Cell Physiol. 2010; 29; 224: 644-648.**
127. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D.  
**Ann Oncol. 2010; 21 Suppl 5:v204-13.**
128. A preliminary study of aquaporin 1 immunolocalization in chronic subdural hematoma membranes. Basaldella L, Perin A, Orvieto E, Marton E, Itskevich D, Dei Tos AP, Longatti P.  
**J Clin Neurosci. 2010;17:905-9'7.**

129. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts.  
**Ann Oncol. 2010; 21 Suppl 5:v98-102**
130. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts.  
**Ann Oncol. 2010; 21 Suppl 5:v198-203**
131. Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn PC, Sciot R, Van Glabbeke M, Verweij J, Blay JY, Hohenberger P, Flanagan A, Dei Tos AP. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.  
**Histopathology. 2010; 57:259-270**
132. Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. The burden of rare cancers in Europe.  
**Adv Exp Med Biol. 2010;686:285-303.**
133. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, Casali PG, Talamini R, Maestro R, Dei Tos AP. Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size.  
**Am J Surg Pathol. 2010; 34:1480-91**
134. Nannini M, Biasco G, Di Scioscio V, Di Battista M, Zompatori M, Catena F, Castellucci P, Paterini P, Dei Tos AP, Stella F, Maleddu A, Pantaleo MA. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (Case reports).  
**Oncol Rep. 2011;25:113-20**
135. Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, Favero F, Mello-Grand M, Dei Tos AP, Elena Giulotto, Giulia Taraboletti, Maurizio D'Incalci, Chiara Mondello. Reduced Expression of the ROCK inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells  
**PLoS One 2010; 30;5: e14154**
136. Corradi D, Alquati S, Bertoni F, Bartoli V, Dei Tos AP, Wenger D, Giannini C. A Small Intraneural Epithelioid Malignant Peripheral Nerve Sheath Tumour of the Median Nerve Simulating a Benign Lesion. Description of a Case and Review of the Literature.  
**Pathol Oncol Res. 2012 Jan;18(1):101-6. Epub 2011 Jan 1.**

137. Mertens F, Romeo S, Bovée JV, Tirabosco R, Athanasou N, Alberghini M, Hogendoorn PC, Dei Tos AP, Sciot R, Domanski HA, Aström K, Mandahl N, Debiec-Rychter M. Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features. **Clin Sarcoma Res. 2011 Oct 13;1(1):10.**
138. Hostein I, Debiec-Rychter M, Olschwang S, Bringuier PP, Toffolati L, Gonzalez D, Forget S, Escande F, Morzuch L, Tamborini E, Faur N, Pilotti S, Dei Tos P, Emile JF, Coindre JM. A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours. **J Gastroenterol. 2011 Feb 1. [Epub ahead of print]**
139. Nannini M, Biasco G, Pallotti MC, Di Battista M, Santini D, Paterini P, Maleddu A, Mandrioli A, Lolli C, Saponara M, Di Scioscio V, Zompatori M, Catena F, Fusaroli P, Dei Tos AP, Pantaleo MA. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. **Med Oncol. 2011 Jan 22. [Epub ahead of print]**
140. Dei Tos AP. Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers. **J Pathol. 2011; 223:565-6.**
141. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. **Ann Oncol. 2011 Apr 4. [Epub ahead of print]**
142. Dei Tos AP, Laurino L, Bearzi I, Messerini L, Farinati F; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Gastrointestinal stromal tumors: the histology report. **Dig Liver Dis. 2011 Mar;43 Suppl 4:S304-9.**
143. Romeo S, Dei Tos AP. Clinical application of molecular pathology in sarcomas. **Curr Opin Oncol. 2011; 23:379-84.**
144. Marton E, Rossi S, Feletti A, Dei Tos AP, Longatti P. Intramedullary malignant peripheral nerve sheath tumor. **J Neurooncol. 2011 May 10. [Epub ahead of print]**
145. Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. PML expression in soft tissue sarcoma:

Prognostic and predictive value in alkylating agents/antracycline-based first line therapy.

**J Cell Physiol. 2011 Jun 15. doi: 10.1002/jcp.22889. [Epub ahead of print]**

146. Challenging differential diagnosis of a wild-type gastrointestinal stromal tumour (GIST) or rare reticular perineurioma of the stomach? The role for mutational analysis. Richter KK, Dempster A, **Dei Tos AP**, Premkumar R, Jackson C.  
**N Z Med J. 2011;124(1331):45-55**
147. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, Casali PG, Dei Tos AP. Natural History of Imatinib-naive GISTs: A Retrospective Analysis of 929 Cases With Long-term Follow-up and Development of a Survival Nomogram Based on Mitotic Index and Size as Continuous Variables.  
**Am J Surg Pathol. 2011; 35:1646-1656**
148. Casali PG, Dei Tos AP. A new journal... on spindle cells.  
**Clin Sarcoma Res. 2011 Jul 25;1(1):1. [Epub ahead of print]**
149. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG. Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers.  
**Gynecol Oncol. 2011;123:553-6**
150. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; The RARECARE working group. Rare cancers are not so rare: The rare cancer burden in Europe.  
**Eur J Cancer. 2011; 47:2493-511**
151. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi B, Bordoni A, Magnusson MK, Linke Z, Jozef Sufliarsky, Massimo F, Jonasson GJ, Dei Tos AP, Rutkowski P. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis of pooled population-based cohorts  
**Lancet Oncol. 2012 Mar;13(3):265-74**
152. Pantaleo MA, Astolfi A, Nannini M, Ceccarelli C, Formica S, Santini D, Heinrich MC, Corless C, Dei Tos AP, Paterini P, Catena F, Maleddu A, Saponara M, Di Battista M, Biasco G. Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours.  
**Histopathology. 2011; 59:1071-1080.**

153. D'Amico FE, Ruffolo C, Romeo S, Massani M, Dei Tos AP, Bassi N. Clear Cell Sarcoma of the Ileum: Report of a Case and Review of the Literature.  
**Int J Surg Pathol. 2011 Dec 30. [Epub ahead of print]**
154. Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.  
**Am J Hematol. 2012 ; 87:22-25**
155. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group.  
**J Clin Oncol. 2012; 10;30:850-6**
156. Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.  
**Eur J Cancer. 2012; 48:159-69.**
157. Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.  
**Eur J Cancer. 2012 ;48:159-69**
158. Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, Franks KN; RARECARE working group. Incidence and survival of rare urogenital cancers in Europe.  
**Eur J Cancer 2012;48:456-64.**
159. Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Stojan P, Licitra L; RARECARE Working Group. Rare cancers of the head and neck area in Europe.  
**Eur J Cancer. 2012;48:783-96.**
160. Siesling S, van der Zwan JM, Izarzugaza I, Jaal J, Treasure T, Foschi R, Ricardi U, Groen H, Tavilla A, Ardanaz E; RARECARE Working Group. Rare thoracic cancers, including peritoneum mesothelioma.

**Eur J Cancer 2012;48:949-60.**

161. Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD, Navarro C, Virgili G; RARECARE WG. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe.  
**Eur J Cancer. 2012;48:1167-75.**
162. Romeo S, Dei Tos AP, Hogendoorn PCW. The clinical impact of molecular techniques on diagnostic pathology of soft tissue and bone tumours,  
**Diagnostic Histopathology 2012, in press.**
163. Ray-Coquard I, Montesco MC, Coindre JM, Dei Tos AP, Lurkin A, Ranchère-Vince D, Vecchiato A, Decouvellaere AV, Mathoulin-Pélissier S, Albert S, Cousin P, Cellier D, Toffolatti L, Rossi CR, Blay JY; for the Conticanet group. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.  
**Ann Oncol. 2012 Feb 13. [Epub ahead of print]**
164. Perrier L, Buja A, Mastrangelo G, Vecchiato A, Sandona P, Ducimetiere F, Blay JY, Gilly FN, Siani C, Biron P, Ranchère-Vince D, Decouvellaere AV, Thiesse P, Bergeron C, Dei Tos AP, Coindre JM, Rossi CR, Ray-Coquard I. Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.  
**BMC Health Serv Res. 2012; 28:12:82**
165. Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY, Buja A, Fedeli U, Cegolon L, Frasson A, Ranchère-Vince D, Montesco C, Ray-Coquard I, Rossi CR. Incidence of soft tissue sarcoma and beyond: A population-based prospective study in 3 European regions.  
**Cancer. 2012 Apr 19. doi: 10.1002/cncr.27555. [Epub ahead of print]**
166. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.  
**Lancet. 2012 19;379:1879-86.**
167. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio

S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

**Cancer. 2012 May 17. doi: 10.1002/cncr.27624. [Epub ahead of print]**

168. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT).

**Ann Oncol. 2012 Jun 17. [Epub ahead of print]**

169. Romeo S, Bovée JV, Kroon HM, Tirabosco R, Natali C, Zanatta L, Sciot R, Mertens F, Athanasou N, Alberghini M, Szuhai K, Hogendoorn PC, Dei Tos AP. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches.

**Virchows Arch. 2012 Sep 22. [Epub ahead of print]**

170. Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonogo M, Rosano C, Dei Tos AP, Doglioni C, Maestro R. A "Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation.

**Cancer Cell. 2012 11;22:404-15.**

171. Nannini M, Pantaleo MA, Catena F, Romano S, Tondo S, Pirini MG, Lolli C, Maleddu A, Mandrioli A, Gatto L, Saponara M, Pallotti MC, Dei Tos AP, Pinna AD, Biasco G. Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report.

**Int J Surg Case Rep. 2012 Sep 19;4(1):7-10.**

172. Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.

**Ann Oncol. 2012 Oct 30. [Epub ahead of print]**

173. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe.

**Eur J Cancer. 2012 Nov;48(17):3257-66.**

174. Vincenzi B, Silletta M, Schiavon G, Frezza AM, Del Vescovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.



**Expert Opin Investig Drugs. 2012 Nov 16. [Epub ahead of print]**

175. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  
**Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9.**
176. ESMO / European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  
**Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55.**
177. ESMO / European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  
**Ann Oncol. 2012 Oct;23 Suppl 7:vii100-9.**
178. Tamborini E, Rossi S, Tarantino E, Mauro V, Dei Tos AP, Pilotti S. Platelet-derived growth factor receptor alpha expression improves the diagnostic assessment of gastrointestinal stromal tumours.  
**Histopathology. 2012; 61:1240-5**
179. Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L; Liguria GIST Unit, Bianchi Scarrà G. Molecular characterization of an Italian series of sporadic GISTs.  
**Gastric Cancer. 2013 Jan 5. [Epub ahead of print]**
180. Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, López-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.  
**Clin Sarcoma Res. 2012 Dec 29;2(1):25. [Epub ahead of print]**
181. Baldi GG, Stacchiotti S, Mauro V, Dei Tos AP, Gronchi A, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S, Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients.  
**Clin Sarcoma Res. 2013 Apr 3;3(1):4. [Epub ahead of print]**
182. van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T; the RARECARE WG. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project.  
**Eur J Cancer. 2013 Mar 27.. [Epub ahead of print]**

183. Antonescu CR, Romeo S, Zhang L, Nafa K, Hornick JL, Nielsen GP, Mino-Kenudson M, Huang HY, Mosquera JM, Dei Tos PA, Fletcher CD. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. **Am J Surg Pathol. 2013 Mar;37(3):385-92**
184. Brenca M, Rossi S, Lorenzetto E, Piccinin E, Piccinin S, Rossi FM, Giuliano A, Dei Tos AP, Maestro R, Modena P. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. **Mol Cancer Ther. 2013 Apr 10. [Epub ahead of print]**
185. Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. Response to chemotherapy of solitary fibrous tumour: A retrospective study. **Eur J Cancer. 2013 Apr 5.. [Epub ahead of print]**
186. Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. **Clin Sarcoma Res. 2013 Apr 17;3(1):6.**
187. Tomek M, Bravi I, Mendoza N, Alsafi A, Mehta A, Molinaro L, Singh P, Radotra B, Dei Tos AP, Roncaroli F. Spinal extradural solitary fibrous tumor with retiform and papillary features. **Ann Diagn Pathol. 2013 Feb 8. doi:p11. [Epub ahead of print]**
188. Sanfilippo R, Dei Tos AP, Casali PG. Myxoid liposarcoma and the mammalian target of rapamycin pathway. **Curr Opin Oncol. 2013 May 13. [Epub ahead of print]**
189. Neuville A, Ranchère-Vince D, Dei Tos AP, Cristina Montesco M, Hostein I, Toffolatti L, Chibon F, Pissaloux D, Alberti L, Decouvelaere AV, Albert S, Riccardo Rossi C, Blay JY, Coindre JM. Impact of Molecular Analysis on the Final Sarcoma Diagnosis: A Study on 763 Cases Collected During a European Epidemiological Study. **Am J Surg Pathol. 2013 Jun 14. [Epub ahead of print]**
190. Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso R, Dalino Ciaramella P, Ventura L, Gambacorta M, Dei Tos AP,

Loli P, Mannelli M, Mantero F, Berruti A, Terzolo M, Papotti M. The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases.

**Am J Surg Pathol. 2013 Jun 14. [Epub ahead of print]**

191. Dal Maso L; AIRTUM Working Group. Lung cancer incidence in young women (20-49 years) reached incidence in young men.

**Epidemiol Prev. 2013 Mar-Jun;37(2-3):187.**

192. Ricci R, Dei Tos AP, Rindi G. GISTogram: a graphic presentation of the growing GIST complexity.

**Virchows Arch. .2013 Aug 23. [Epub ahead of print]**

193. Di Giorgio E, Clocchiatti A, Piccinin S, Sgorbissa A, Viviani G, Peruzzo P, Romeo S, Rossi S, Dei Tos AP, Maestro R, Brancolini C. MEF2 Is a Converging Hub for Histone Deacetylase 4 and Phosphatidylinositol 3-Kinase/Akt-Induced Transformation.

**Mol Cell Biol. 2013; 33:4473-91.**

194. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study.

**Mol Cancer Ther. 2013 Oct 21. [Epub ahead of print]**

195. Ricci R, Dei Tos AP, Rindi G On the prevalence of KRAS mutations in GISTs.

**Virchows Arch. 2013 Oct 19. [Epub ahead of print]**

196. Dei Tos AP Liposarcomas: diagnostic pitfalls and new insights.

**Histopathology. 2014 Jan;64(1):38-52.**

197. Stacchiotti S, Marrari A, Dei Tos AP, Casali PG. Targeted Therapies in Rare Sarcomas: IMT, ASPS, SFT, PEComa, and CCS.

**Hematol Oncol Clin North Am. 2013 Oct;27(5):1049-61.**

198. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the

French Sarcoma Group.

**Ann Oncol. 2013 Dec 9. [Epub ahead of print]**

199. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P, Casali PG. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group.  
**Eur J Cancer. 2013 Dec 5. [Epub ahead of print]**
200. Pisani P, Buzzoni C, Dal Maso L; AIRTUM Working Group. Cancer incidence in 0-14-year children shows little geographical differences.  
**Epidemiol Prev. 2013 Jul-Oct;37(4-5):342.**
201. Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, Casali PG Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.  
**Clin Sarcoma Res. 2013 Dec 18;3(1):16.**
202. Dei Tos AP. A current perspective on the role for molecular studies in soft tissue tumor pathology.  
**Semin Diagn Pathol. 2013; 30:375-81.**
203. Gronchi A, Colombo C, Le Pécoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.  
**Ann Oncol. 2013 Dec 9. [Epub ahead of print]**
204. Cacciatore M, Dei Tos AP. Challenging epithelioid mesenchymal neoplasms: mimics and traps.  
**Pathology 2014;46(2):126-34**
205. AIRTUM Working Group. Italian cancer figures, report 2013: Multiple tumours.  
**Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152**
206. Vogel D, Righi A, Kreshak J, Dei Tos AP, Merlino B, Brunocilla E, Vanel D. Lipofibromatosis: magnetic resonance imaging features and pathological correlation in three cases.  
**Skeletal Radiol. 2014 Feb 8. [Epub ahead of print]**

207. Crocetti E, Rondelli R, Dal Maso L; AIRTUM Working Group. About 1,400 new cancer diagnosis in Italian children (0-14 years) are attended every year (7,000 in 5 years).  
**Epidemiol Prev. 2013 Nov-Dec;37(6):410**
208. Tucci M, Stucci S, Vallarelli S, Gesualdo L, Brunetti O, Dei Tos AP, Silvestris F. Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer.  
**J Clin Oncol. 2014 Mar 24. [Epub ahead of print]**
209. Feletti A, Marton E, Bendini M, Zanatta L, Valori L, Dei Tos AP, Di Paola F, Longatti P, Rossi S. Anaplastic ependymoma of the third ventricle.  
**Brain Tumor Pathol. 2014 Mar 19. [Epub ahead of print]**
210. Sambataro M, Seganfredo E, Canal F, Furlan A, Del Pup L, Niero M, Paccagnella A, Gherlinzoni F, Dei Tos AP. Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.  
**Int J Vasc Med. 2014. Epub 2014 Feb 3.**
211. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, Dei Tos AP, van der Graaf WT; for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.  
**Lancet Oncol. 2014;15:415-23.**
212. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.  
**Eur J Cancer. 2014 Apr 2. [Epub ahead of print]**
213. Oudijk L, de Krijger RR, Rapa I, Beuschlein F, de Cubas AA, Dei Tos AP, Dinjens WN, Korpershoek E, Mancikova V, Mannelli M, Papotti M, Vatrano S, Robledo M, Volante M. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series.  
**J Clin Endocrinol Metab. 2014 Mar 31: [Epub ahead of print]**
214. Fusco M, Trama A, Buzzoni C; AIRTUM Working Group. In the last 15 years, survival in Italian children (0-14 years) is increased to 12%.  
**Epidemiol Prev. 2014 Jan-Feb;38(1):62.**
215. Dal Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D,

Caldarella A, Dei Tos AP, Falcini F, Autelitano M, Masanotti G, Ferretti S, Tisano F, Tirelli U, Crocetti E, De Angelis R; the AIRTUM Working group. Long-term survival, prevalence, and cure of cancer: A population-based estimation for 818,902 Italian patients and 26 cancer types.

**Ann Oncol. 2014 Aug 22. pii: mdu383. [Epub ahead of print]**

216. Crocetti E, Madeddu A, Mangone L; AIRTUM Working Group; AIRTUM Working Group [In 2014 cancer registration covers more than half of the Italian population].

**Epidemiol Prev. 2014 May-Aug;38(3-4):273.**

217. Toffolatti L, Scquizzato E, Cavallin S, Canal F, Scarpa M, Stefani PM, Gherlinzoni F, Dei Tos AP MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.

**Virchows Arch. 2014 Jul 17. [Epub ahead of print]**

218. Buzzoni C, Ferretti S, Dal Maso L; AIRTUM Working Group [After the increasing trend in the Nineties, in Italy incidence of tumours in children (0-14 years) is decreasing].

**Epidemiol Prev. 2014 Mar-Apr;38(2):146.**

219. Comba P, Ricci P, Iavarone I, Pirastu R, Buzzoni C, Fusco M, Ferretti S, Fazzo L, Pasetto R, Zona A, Crocetti E; ISS-AIRTUM Working Group for the study of cancer incidence in contaminated sites. Cancer incidence in Italian contaminated sites.

**Ann Ist Super Sanita. 2014;50(2):186-91.**

220. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, Dei Tos AP. [Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.](#)

**Gut. 2014 Sep 1. pii: gutjnl-2014-307508. [Epub ahead of print]**

221. Righi A, Gambarotti M, Picci P, Dei Tos AP, Vanel D. [Primary pseudomyogenic haemangioendothelioma of bone: report of two cases.](#)

**Skeletal Radiol. 2014 Oct 11. [Epub ahead of print]**

222. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. [Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.](#)

**Eur J Cancer. 2014 Sep 27. [Epub ahead of print]**

223. ESMO/European Sarcoma Network Working Group. [Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.](#)

**Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6.**

224. ESMO/European Sarcoma Network Working Group. [Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.](#) **Ann Oncol. 2014 Sep;25 Suppl 3:iii113-23. doi:**
225. ESMO/European Sarcoma Network Working Group. [Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.](#) **Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12**
226. Stiller CA, Trama A, Brewster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; RARECARE Working Group. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project.
227. Zanatta L, Valori L, Cappelletto E, Pozzebon ME, Pavan E, Dei Tos AP, Merkle D. Reagent and Labor Cost Optimization through Automation of Fluorescence In Situ Hybridization (FISH) with the VP 2000: An Italian Case Study. **J Lab Autom. 2014 Nov 13. pii: 2211068214558294.**
228. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. **Clin Sarcoma Res. 2014 Nov 22;4(1):16**
229. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S. Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. **Am J Surg Pathol. 2015 Jan 9. [Epub ahead of print]**
230. Gasparotto D, Rossi S, Campagna D, Scavina P, Tiziano FD, Marzotto A, Toffolatti L, Vitelli CE, Amini M, Dei Tos AP, Maestro R. Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor. **J Clin Oncol. 2014 Dec 29. pii: JCO.2012.44.7300. [Epub ahead of print]**
231. Lartigue L, Neuville A, Lagarde P, Brulard C, Rutkowski P, Dei Tos P, Wardelmann E, Debiec-Rychter M, Italiano A, Coindre JM, Chibon F. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy. **Eur J Cancer. 2015 Jan;51(1):75-83.**
232. Righi A, Gambarotti M, Longo S, Benini S, Gamberi G, Cocchi S, Vanel D, Picci P, Bertoni F, Simoni A, Franchi A, Dei Tos A. Small Cell

Osteosarcoma: Clinicopathologic, Immunohistochemical, and Molecular Analysis of 36 Cases.

**Am J Surg Pathol. 2015 Feb 26. [Epub ahead of print]**

233. Blay JY, Casali PG, Dei Tos AP, Le Cesne A, Reichardt P. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.

**Oncology. 2015 Feb 26. [Epub ahead of print]**

234. Romeo S, Rossi S, Acosta Marín M, Canal F, Sbaraglia M, Laurino L, Mazzoleni G, Montesco MC, Valori L, Campo Dell'Orto M, Gianatti A, Lazar AJ, Dei Tos AP. Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases.

**Clin Sarcoma Res. 2015 Feb 12;5:7**

235. Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.

**Anticancer Drugs. 2015 Mar 11. [Epub ahead of print]**

236. Dal Maso L, Guzzinati S, De Angelis R; AIRTUM Working Group. Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy.

**Epidemiol Prev. 2014;38(6 Suppl 1):1-122**

237. Vincenzi B, D'Onofrio L, Frezza AM, Grasso RF, Fausti V, Santini D, Dei Tos AP, Tonini G. Classic Kaposi Sarcoma: to treat or not to treat?

**BMC Res Notes. 2015; 10;8(1):138.**

Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. Deregulation of dicer and mir-155 expression in liposarcoma.

**Oncotarget. 2015 Apr 4. [Epub ahead of print]**

238. Crocetti E, Buzzoni C, Dal Maso L; AIRTUM Working Group. [Italy 2014: 1,000 new cancer cases every day, but mortality is decreasing].

**Epidemiol Prev. 2015 Jan-Feb;39(1):62**

239. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, Casali PG, Maestro R, Dei Tos AP. KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST: A Population-based Study.



**Am J Surg Pathol. 2015 Apr 8. [Epub ahead of print]**

240. Sandrucci S, Gatta G, Trama A, Dei Tos AP, Casali PG. Specialized teams or specialist networks for rare cancers?

**Eur J Surg Oncol. 2015 Apr 23. [Epub ahead of print]**

241. Lupato V, Romeo S, Franchi A, Mantovani M, Dei Tos AP, Tirelli G, Da Mosto MC, Boscolo-Rizzo P. Head and Neck Extranodal Interdigitating Dendritic Cell Sarcoma: Case Report and Review of the Literature.

**Head Neck Pathol. 2015 Apr 19. [Epub ahead of print]**

242. Crocetti E, Buzzoni C, Dal Maso L; AIRTUM Working Group. [The risk of cancer is slightly higher among Italian cancer patients than in the general population].

**Epidemiol Prev. 2015 Mar-Apr;39(2):140.**

243. Paganini I, Sestini R, Cacciatore M, Capone GL, Candita L, Paoletto C, Sbaraglia M, Dei Tos AP, Rossi S, Papi L.

Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosis.

**Hum Pathol. 2015 May 6. [Epub ahead of print]**

244. Righi A, Gambarotti M, Sbaraglia M, Frisoni T, Donati D, Vanel D, Dei Tos AP. Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis.

**Clin Sarcoma Res. 2015 Jun 6;5:15.**

245. Di Liso E, Pennelli N, Lodovichetti G, Ghiotto C, Dei Tos AP, Conte P, Bonanno L. BRAF mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.

**Cancer Biol Ther 2015 Jun 5:0. [Epub ahead of print]**

246. Righi A, Gambarotti M, Manfrini M, Benini S, Gamberi G, Cocchi S, Casadei R, Picci P, Vanel D, Dei Tos AP. Sclerosing epithelioid fibrosarcoma of the thigh: report of two cases with synchronous bone metastases.

**Virchows Arch. 2015 Jul 26. [Epub ahead of print]**

247. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP).

**Clin Cancer Res. 2015 Aug 10. [Epub ahead of print]**

248. Fedeli U, Zorzi M, Urso ED, Gennaro N, Dei Tos AP, Saugo M. Impact of fecal immunochemical test-based screening programs on proximal and distal colorectal cancer surgery rates: A natural multiple-baseline experiment. **Cancer. 2015 Aug 11. doi: 10.1002/cncr.29623. [Epub ahead of print]**
249. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. **Oncotarget. 2015 Sep 24. [Epub ahead of print]**
250. Torrisi A, Castaing M, Giacomini A, Luminari S, Mangone L; AIRTUM Working Group. [AIRTUM and SIE for a shared definition of haemolymphopoietic cancers]. **Epidemiol Prev. 2015 Mar-Apr;39(2):208**
251. Gambarotti M, Righi A, Picci P, Bertoni F, Manfrini M, Donati D, Dei Tos A, Vanel D. Pediatric chondrosarcomas: a retrospective review of 17 cases. **Histopathology. 2015 Sep 26. doi: 10.1111/his.12881. [Epub ahead of print]**
252. Buzzoni C, Crocetti E, De Angelis R, Dal Maso L; AIRTUM Working Group. [Cancer survival in Italy in 2000-2007 is better than in Europe]. **Epidemiol Prev. 2015 Jul-Aug;39(4):270**
253. Scarpa M, Ruffolo C, Canal F, Scarpa M, Basato S, Erroi F, Fiorot A, Dall'Agnese L, Pozza A, Porzionato A, Castagliuolo I, Dei Tos AP, Bassi N, Castoro C. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. **Oncotarget. 2015 Oct 19 [Epub ahead of print]**
254. Righi A, Paioli A, Dei Tos AP, Gambarotti M, Palmerini E, Cesari M, Marchesi E, Donati DM, Picci P, Ferrari S. High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma? **Clin Sarcoma Res. 2015 Oct 29;5:23**
255. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, **Dei Tos AP**, MARRÉAUD S, van der Graaf WT, Zalcborg JR, Litière S, Blay JY. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

256. Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, Valori L, Lamon S, Dei Tos AP, Maestro R. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.  
**J Pathol. 2015 Nov 26. doi: 10.1002/path.4677. [Epub ahead of print]**
257. Rossi S, Sbaraglia M, Dell'Orto MC, Gasparotto D, Cacciatore M, Boscato E, Carraro V, Toffolatti L, Gallina G, Niero M, Pillozzi E, Mandolesi A, Sessa F, Sonzogni A, Mancini C, Mazzoleni G, Romeo S, Maestro R, Dei Tos AP. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.  
**Oncotarget. 2016 Apr 16. doi: 10.18632/oncotarget.8768. [Epub ahead of print]**
258. Gambarotti M, Benini S, Gamberi G, Cocchi S, Palmerini E, Sbaraglia M, Donati D, Picci P, Vanel D, Ferrari S, Righi A, Dei Tos AP. CIC-DUX4 Fusion-Positive Round Cell Sarcomas of soft tissue and bone: a single institution morphologic and molecular analysis of 7 cases.  
**Histopathology. 2016 Apr 15. doi: 10.1111/his.12985. [Epub ahead of print]**
259. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Pechoux CL, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG, Gronchi A. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.  
**Lancet Oncol. 2016 May;17(5):671-80**
260. Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomini A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, DalMaso L; AIRTUM Working Group. Italian cancer figures - Report 2015: The burden of rare cancers in Italy.  
**Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120.**
261. Dal Maso L, Buzzoni C, Guzzinati S, Crocetti E; AIRTUM Working Group [Italy 2015: 3 million Italians are living after a cancer diagnosis, both incidence and mortality are decreasing].
262. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E,

Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

**Eur J Cancer. 2017 Mar 8;76:84-92. [Epub ahead of print]**

263. Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

**Clin Sarcoma Res. 2016 Sep 14;6(1):15.**

264. Colia V, Provenzano S, Morosi C, Collini P, Renne SL, Dagrada PG, Sangalli C, Dei Tos AP, Marrari A, Casali PG, Stacchiotti S. Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review.

**Clin Sarcoma Res. 2016 Sep 1;6(1):16.**

265. Righi A, Gambarotti M, Sbaraglia M, Sisto A, Ferrari S, Dei Tos AP, Picci P. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.

**Hum Pathol. 2016; 58:15-23.**

266. Quero G, Musarra T, Carrato A, Fici M, Martini M, Dei Tos AP, Alfieri S, Ricci R. Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature.

**Medicine (Baltimore). 2016 Jul;95(28):**

267. Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, Pilotti S, Gronchi A, Dei Tos AP, Maestro R. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.

**Clin Cancer Res. 2017; 23:273-282.**

268. Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.

**Ann Surg Oncol. 2016; 23:2735-44.**

269. Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma

Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.

**Mol Cancer Res. 2016;14:820-9**

270. Ray-Coquard I, Rizzo E, Blay JY, Casali P, Judson I, Hansen AK, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Litière S, Rutkowski P, Hohenberger P, Gronchi A, van der Graaf WT. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.

**Gynecol Oncol. 2016; 142:95-101**

271. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davi MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative., Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Whole-genome landscape of pancreatic neuroendocrine tumours.

**Nature. 2017; 543:65-71**

272. Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

**Ann Oncol. 2016; 27: 2283-2288**

273. Gambarotti M, Righi A, Vanel D, Cocchi S, Benini S, Elli FM, Mantovani G, Ruggieri P, Boriani S, Donati D, Sbaraglia M, Dei Tos AP, Picci P. Fibrocartilaginous mesenchymoma of bone: a single-institution experience with molecular investigations and a review of the literature.

**Histopathology. 2017 Feb 26. [Epub ahead of print]**

274. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.  
**Eur J Cancer 2017; 8 :84-92.**
275. Ruffolo C, Toffolatti L, Canal F, Kotsafti A, Pagura G, Pozza A, Campo Dell'Orto M, Ferrara F, Massani M, Dei Tos AP, Castoro C, Bassi N, Scarpa M. Colorectal polypoid lesions and expression of vascular endothelial growth factor in a consecutive series of endoscopic and surgical patients.  
**Tumour Biol. 2017 Mar;39(3)**
276. Di Giorgio E, Franforte E, Cefalù S, Rossi S, Dei Tos AP, Brenca M, Polano M, Maestro R, Paluvai H, Picco R, Brancolini C. The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness.  
**PLoS Genet. 2017 Apr 18 [Epub ahead of print]**
277. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; CONCORD Working Group. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries.  
**Lancet Haematol. 2017 Apr 11. [Epub ahead of print]**
278. Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, Giovanni Casali P, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma.  
**Genes Chrom Cancer 2017. [Epub ahead of print]**
279. D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.  
**Eur J Cancer. 2017;78:122-132.**
280. Gambarotti M, Righi A, Frisoni T, Donati D, Vanel D, Sbaraglia M, Dei Tos AP. Dedifferentiated chondrosarcoma with "adamantinoma-like" features: A case report and review of literature.  
**Pathol Res Pract. 2017 May**

281. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.  
**Lancet Oncol. 2017 May 9. [Epub ahead of print]**
282. Mancini I, Righi A, Gambarotti M, Picci P, Dei Tos AP, Billings SD, Simi L, Franchi A. Phenotypic and molecular differences between giant cell tumor of soft tissue and its bone counterpart.  
**Histopathology. 2017 May 6. [Epub ahead of print]**
283. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue.  
**Oncotarget 2017 May 17. [Epub ahead of print]**
284. Bianchi G, Sambri A, Righi A, Dei Tos AP, Picci P, Donati D. Histology and grading are important prognostic factors in synovial sarcoma.  
**Eur J Surg Oncol. 2017 [Epub ahead of print]**
285. Furlan C, Polesel J, Barzan L, Franchin G, Sulfaro S, Romeo S, Colizzi F, Rizzo A, Baggio V, Giacomarra V, Dei Tos AP, Boscolo-Rizzo P, Vaccher E, Dolcetti R, Sigalotti L, Fratta E. Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma.  
**Clin Epigenetics. 2017 May 30;9:58**
286. D'Amico FE, Ruffolo C, Romano M, Di Domenico M, Sbaraglia M, Dei Tos AP, Garofalo T, Giordano A, Bassi I, Massani M. Rare Neoplasm Mimicking Neuroendocrine Pancreatic Tumor: A Case Report of Solitary Fibrous Tumor with Review of the Literature.  
**Anticancer Res. 2017 Jun;37(6):3093-3097**
287. Sbaraglia M, Righi A, Gambarotti M, Vanel D, Picci P, Dei Tos AP. Soft Tissue Tumors Rarely Presenting Primary in Bone; Diagnostic Pitfalls.  
**Surg Pathol Clin. 2017 Sep;10(3):705-730**
288. Rossi S, Gasparotto D, Cacciatore M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, Gronchi A, Reuss DE, von Deimling A, Maestro R, Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs.  
**Mod Pathol. 2017 Sep 1. [Epub ahead of print]**
289. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, Gronchi A, Casali PG, Sanfilippo R. Activity of anthracycline- and

ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.

**Clin Sarcoma Res. 2017 Aug 22;7:1**

290. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.

**Br J Cancer. 2017 Jul 25;117(3):340-346**

291. Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C, Dei Tos AP, Simi L, Pinzani P, Franchi A. Histone 3.3 Mutations in Giant Cell Tumor and Giant Cell-Rich Sarcomas of Bone.

**Hum Pathol. 2017 Sep 9. pii: S0046-8177(17)30322-2**

292. Rossi S, Gasparotto D, Cacciatore M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, Gronchi A, Reuss DE, von Deimling A, Maestro R, Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs.

**Mod Pathol. 2017 Sep 1. doi: 10.1038/modpathol.2017.105. [Epub ahead of print]**

293. Mandrioli M, Mastrangelo L, Masetti M, Zanini N, Lega S, Nannini M, Gruppioni E, Altimari A, Dei Tos AP, Fabbri C, Jovine E. Characterization of malignant gastrointestinal stromal tumors-a single center experience.

**J Gastrointest Oncol 2017; 8:1037-1045.**

294. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.

**Eur J Cancer 2018; 20;93:28-36.**

295. Sambataro M, Sambado L, Trevisiol E, Cacciatore M, Furlan A, Stefani PM, Seganfredo E, Durante E, Conte S, Della Bella S, Paccagnella A, Dei Tos AP. Proinsulin-expressing dendritic cells in type 2 neuropathic diabetic patients with and without foot lesions.

**FASEB J. 2018 Feb 12: [Epub ahead of print]**

296. Righi A, Sbaraglia M, Gambarotti M, Cocchi S, Drago G, Casadei R, Picci P,



Vanel D, Dei Tos AP. Extra-axial chordoma: a clinicopathologic analysis of six cases.

**Virchows Arch 2018 Mar 20. [Epub ahead of print]**

297. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, Casali PG, Stacchiotti S, Pantaleo MA. Identification of an Actionable Mutation of KIT in a Case of Extraskelletal Myxoid Chondrosarcoma.

**Int J Mol Sci. 2018 Jun 23;19 (7).**

298. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desai IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

**JAMA Oncol. 2018 Apr 12 [Epub ahead of print]**

299. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

**Ann Oncol. 2018 May 28. [Epub ahead of print]**

300. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

**Ann Oncol. 2018 May 28. [Epub ahead of print]**

301. Dei Tos AP, Bonvalot S, Haas R. The key role of pathology, surgery and radiotherapy in the initial management of soft tissue sarcoma.  
**Future Oncol. 2018 May;14(10s):15-23.**
302. Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, Stacchiotti S. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.  
**Anticancer Drugs. 2018;29:589-595.**

## Chapters in Books

303. "Patologia e diagnosi dei GIST. In M Lopez (ed) GIST: tumori stromali gastrointestinali." Dei Tos AP, Ninfo V. S.  
**Editrice Universo Roma, 2005, pp. 15-22**
304. "Patologia e diagnosi dei GIST. In M Lopez (ed) GIST: tumori stromali gastrointestinali." Dei Tos AP, Ninfo V. S.  
**Editrice Universo Roma, 2005, pp. 15-22**
305. "Atypical lipomatous tumour/Well-differentiated liposarcoma". Dei Tos AP, Pedetour F.  
**In: Pathology and Genetics: Tumors of Soft Tissue and Bone. IARC Press, Lyon, 2002: 35-37.**
306. "Dedifferentiated Liposarcoma". Dei Tos AP, Pedetour F.  
**In: Pathology and Genetics: Tumors of Soft Tissue and Bone. IARC Press, Lyon, 2002: 38-39.**
307. Adipocytic tumors. Dei Tos AP.  
**In Folpe AL, Inwards CW (eds). Bone and Soft Tissue pathology. Saunders, Philadelphia 2010:97-118.**
308. La patologia. Dei Tos AP  
**In Comandone A, Barni S (eds) I sarcomi dei Tessuti Molli. Il Pensiero Scientifico Editore Roma 2011: 7-26.**
309. Anatomic and Clinical Pathology. De Chiara A. Dei Tos AP  
**Messina E. Gastrointestinal Stromal Tumors. Springer Verlag Italia, 2011: 3-14.**
310. Istopatologia dei Tumori Rari  
**Licitra L. Olmi p (Eds) Tumori della Testa e del Collo Springer Verlag Italia 2011: 47-66.**
311. "Atypical lipomatous tumour/Well-differentiated liposarcoma". Dei Tos AP, Pedetour F.  
**In: WHO Classification of Tumors of Soft Tissue and Bone. IARC, Lyon, 2013: 35-37.**
312. "Dedifferentiated Liposarcoma". Dei Tos AP, Pedetour F.  
**In: Pathology and Genetics: Tumors of Soft Tissue and Bone. IARC, Lyon, 2013: 38-39.**

313. "Adipocytic tumor". L. Laurino Dei Tos AP,  
**In: Hornick JL. Practical Soft Tissue Pathology. A diagnostic Approach Elsevier, Philadelphia 2013: 293-321.**
314. Gastrointestinal Stromal Tumor. Casali PG, Dei Tos AP, Gronchi A.  
**In: De Vita V. Cancer. Principle & Practice of Oncology. 10<sup>th</sup> Edition, Walters Kluwer, 2015: 745-756.**

Treviso, 25 giugno 2018

Prof. Angelo Paolo Dei Tos



Il sottoscritto dichiara, di aver preso visione dell'informativa ai sensi dell'art. 13 del D. Lgs. 196/03 in materia di protezione dei dati personali, ed autorizza al trattamento dei propri dati personali riportati nella presente autocertificazione e nel curriculum vitae fornito, nel pieno rispetto di quanto indicato dall'informativa stessa, nonché degli obblighi di correttezza, libertà e trasparenza imposti dal predetto D.Lgs n. 196/03.

Treviso, 25 giugno 2018

Prof. Angelo Paolo Dei Tos

